Skip to main content
Top
Published in: Nutrition & Metabolism 1/2015

Open Access 01-12-2015 | Review

Effects of Zinc supplementation on serum lipids: a systematic review and meta-analysis

Authors: Priyanga Ranasinghe, WS Wathurapatha, MH Ishara, R. Jayawardana, P. Galappatthy, P. Katulanda, GR Constantine

Published in: Nutrition & Metabolism | Issue 1/2015

Login to get access

Abstract

Zinc is a mineral that plays a vital role in many biological processes and plays an important role in insulin action and carbohydrate metabolism. It may also have a protective role in the prevention of atherogenesis. Numerous studies have evaluated the effects of Zinc supplementation on serum lipids in humans and have demonstrated varying results. We systematically evaluated the literature and performed a meta-analysis on the effects of Zinc supplementation on serum lipids. A five staged comprehensive search of the literature was conducted in the following databases; PubMed, Web of Science and SciVerse Scopus for studies published before 31st December 2014. All controlled clinical trial in humans, that included a Zinc supplement intervention, either alone or in combination with other micronutrients and evaluated effects on serum lipids (total cholesterol [TC], triglycerides [TG], LDL cholesterol [LDL-c] and HDL cholesterol [HDL-c]). A meta-analysis of selected studies was performed using RevMan v5.3. The Jaded scale was used to assess the methodological quality of the trials included in the systematic review. A total of 24 studies were included in Meta analysis, which included a total of 33 Zinc interventions, in a total of 14,515 participants in the Zinc intervention or control group. The duration of Zinc supplementation ranged from 1 month to 7.5 years. The dose of elemental Zinc supplemented ranged from 15–240 mg/day. The pooled mean difference for TC between Zinc supplemented and placebo groups from random effects analysis was −10.92 mg/dl (95 % CI: −15.33, −6.52; p < 0.0001, I2 = 83 %), while for HDL cholesterol it was 2.12 mg/dl (95 % CI: −0.74, 4.98; p = 0.15, I2 = 83 %). The pooled mean difference for LDL-c between Zinc supplemented and placebo group from random effect analysis was −6.87 mg/dl (95 % CI: −11.16,-2.58; p < 0.001, I2 = 31) and for TG it was −10.92 mg/dl (95 % CI: −18.56, − 3.28; p < 0.01, I2 = 69 %). In conclusion, Zinc supplementation has favourable effects on plasma lipid parameters. Zinc supplementation significantly reduced total cholesterol, LDL cholesterol and triglycerides. Therefore it may have the potential to reduce the incidence of atherosclerosis related morbidity and mortality.
Literature
1.
go back to reference King JC, Cousins RJ. Zinc. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, editors. Modern Nutrition in Health and Disease. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 271–85. King JC, Cousins RJ. Zinc. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, editors. Modern Nutrition in Health and Disease. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 271–85.
2.
go back to reference Coleman JE. Zinc proteins: enzymes, storage proteins, transcription factors, and replication proteins. Annu Rev Biochem. 1992;61:897–946.CrossRef Coleman JE. Zinc proteins: enzymes, storage proteins, transcription factors, and replication proteins. Annu Rev Biochem. 1992;61:897–946.CrossRef
3.
go back to reference Vallee BL, Falchuk KH. The biochemical basis of zinc physiology. Physiol Rev. 1993;73(1):79–118. Vallee BL, Falchuk KH. The biochemical basis of zinc physiology. Physiol Rev. 1993;73(1):79–118.
4.
go back to reference Chausmer AB. Zinc, insulin and diabetes. J Am Coll Nutr. 1998;17(2):109–15.CrossRef Chausmer AB. Zinc, insulin and diabetes. J Am Coll Nutr. 1998;17(2):109–15.CrossRef
5.
go back to reference Pidduck HG, Wren PJ, Evans DA. Hyperzincuria of diabetes mellitus and possible genetical implications of this observation. Diabetes. 1970;19(4):240–7.CrossRef Pidduck HG, Wren PJ, Evans DA. Hyperzincuria of diabetes mellitus and possible genetical implications of this observation. Diabetes. 1970;19(4):240–7.CrossRef
6.
go back to reference Garg VK, Gupta R, Goyal RK. Hypozincemia in diabetes mellitus. J Assoc Physicians India. 1994;42(9):720–1. Garg VK, Gupta R, Goyal RK. Hypozincemia in diabetes mellitus. J Assoc Physicians India. 1994;42(9):720–1.
7.
go back to reference Kelly F. Use of antioxidants in the prevention and treatment of disease. J Int Fed Clin Chem. 1998;10(1):21–3. Kelly F. Use of antioxidants in the prevention and treatment of disease. J Int Fed Clin Chem. 1998;10(1):21–3.
8.
go back to reference World Health Organisation: Quantifying selected major risks to health. In: The World Health Report Geneva; 2002 World Health Organisation: Quantifying selected major risks to health. In: The World Health Report Geneva; 2002
9.
go back to reference Black RE. Zinc deficiency, infectious disease and mortality in the developing world. J Nutr. 2003;133(5 Suppl 1):1485S–9S. Black RE. Zinc deficiency, infectious disease and mortality in the developing world. J Nutr. 2003;133(5 Suppl 1):1485S–9S.
10.
go back to reference Hambidge M, Krebs NF. Interrelationships of key variables of human zinc homeostasis: relevance to dietary zinc requirements. Annu Rev Nutr. 2001;21:429–52.CrossRef Hambidge M, Krebs NF. Interrelationships of key variables of human zinc homeostasis: relevance to dietary zinc requirements. Annu Rev Nutr. 2001;21:429–52.CrossRef
11.
go back to reference Prasad AS. Clinical spectrum of human zinc deficiency. In: Prasad AS, editor. Biochemistry of zinc. New York: Plenum Press; 1993. p. 219–58.CrossRef Prasad AS. Clinical spectrum of human zinc deficiency. In: Prasad AS, editor. Biochemistry of zinc. New York: Plenum Press; 1993. p. 219–58.CrossRef
12.
go back to reference Beattie JH, Gordon MJ, Rucklidge GJ, Reid MD, Duncan GJ, Horgan GW, et al. Aorta protein networks in marginal and acute zinc deficiency. Proteomics. 2008;8(10):2126–35.CrossRef Beattie JH, Gordon MJ, Rucklidge GJ, Reid MD, Duncan GJ, Horgan GW, et al. Aorta protein networks in marginal and acute zinc deficiency. Proteomics. 2008;8(10):2126–35.CrossRef
13.
go back to reference Beattie JH, In-Sook K. Is zinc deficiency a risk factor for atherosclerosis? Br J Nutr. 2004;91:177–81.CrossRef Beattie JH, In-Sook K. Is zinc deficiency a risk factor for atherosclerosis? Br J Nutr. 2004;91:177–81.CrossRef
14.
go back to reference Meerarani P, Ramadass P, Toborek M, Bauer HC, Bauer H, Hennig B. Zinc protects against apoptosis of endothelial cells induced by linoleic acid and tumor necrosis factor alpha. Am J Clin Nutr. 2000;71(1):81–7. Meerarani P, Ramadass P, Toborek M, Bauer HC, Bauer H, Hennig B. Zinc protects against apoptosis of endothelial cells induced by linoleic acid and tumor necrosis factor alpha. Am J Clin Nutr. 2000;71(1):81–7.
15.
go back to reference Reiterer G, MacDonald R, Browning JD, Morrow J, Matveev SV, Daugherty A, et al. Zinc deficiency increases plasma lipids and atherosclerotic markers in LDL-receptor-deficient mice. J Nutr. 2005;135(9):2114–8. Reiterer G, MacDonald R, Browning JD, Morrow J, Matveev SV, Daugherty A, et al. Zinc deficiency increases plasma lipids and atherosclerotic markers in LDL-receptor-deficient mice. J Nutr. 2005;135(9):2114–8.
16.
go back to reference Singh RB, Niaz MA, Rastogi SS, Bajaj S, Gaoli Z, Shoumin Z. Current zinc intake and risk of diabetes and coronary artery disease and factors associated with insulin resistance in rural and urban populations of North India. J Am Coll Nutr. 1998;17(6):564–70.CrossRef Singh RB, Niaz MA, Rastogi SS, Bajaj S, Gaoli Z, Shoumin Z. Current zinc intake and risk of diabetes and coronary artery disease and factors associated with insulin resistance in rural and urban populations of North India. J Am Coll Nutr. 1998;17(6):564–70.CrossRef
17.
go back to reference Hashemipour M, Kelishadi R, Shapouri J, Sarrafzadegan N, Amini M, Tavakoli N, et al. Effect of zinc supplementation on insulin resistance and components of the metabolic syndrome in prepubertal obese children. Hormones. 2009;8(4):279–85.CrossRef Hashemipour M, Kelishadi R, Shapouri J, Sarrafzadegan N, Amini M, Tavakoli N, et al. Effect of zinc supplementation on insulin resistance and components of the metabolic syndrome in prepubertal obese children. Hormones. 2009;8(4):279–85.CrossRef
18.
go back to reference Afkhami-Ardekani M, Karimi M, Mohammadi SM, Nourani F. Effect of zinc sulfate supplementation on lipid and glucose in type 2 diabetic patients. Pak J Nutr. 2008;7(4):550–3.CrossRef Afkhami-Ardekani M, Karimi M, Mohammadi SM, Nourani F. Effect of zinc sulfate supplementation on lipid and glucose in type 2 diabetic patients. Pak J Nutr. 2008;7(4):550–3.CrossRef
19.
go back to reference Partida-Hernández G, Arreola F, Fenton B, Cabeza M, Román-Ramos R, Revilla-Monsalve MC. Effect of zinc replacement on lipids and lipoproteins in type 2-diabetic patients. Biomed Pharmacother. 2006;60(4):161–8.CrossRef Partida-Hernández G, Arreola F, Fenton B, Cabeza M, Román-Ramos R, Revilla-Monsalve MC. Effect of zinc replacement on lipids and lipoproteins in type 2-diabetic patients. Biomed Pharmacother. 2006;60(4):161–8.CrossRef
20.
go back to reference Kadhim HM, Ismail SH, Hussein KI, Bakir IH, Sahib AS, Khalaf BH, et al. Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin. J Pineal Res. 2006;41(2):189–93.CrossRef Kadhim HM, Ismail SH, Hussein KI, Bakir IH, Sahib AS, Khalaf BH, et al. Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin. J Pineal Res. 2006;41(2):189–93.CrossRef
21.
go back to reference Kim J, Lee S. Effect of zinc supplementation on insulin resistance and metabolic risk factors in obese Korean women. Nutrition Research and Practice. 2012;6(3):221–5.CrossRef Kim J, Lee S. Effect of zinc supplementation on insulin resistance and metabolic risk factors in obese Korean women. Nutrition Research and Practice. 2012;6(3):221–5.CrossRef
22.
go back to reference Roozbeh J, Hedayati P, Sagheb MM, Sharifian M, Jahromi AH, Shaabani S, et al. Effect of zinc supplementation on triglyceride, cholesterol, LDL, and HDL levels in zinc-deficient hemodialysis patients. Ren Fail. 2009;31(9):798–801.CrossRef Roozbeh J, Hedayati P, Sagheb MM, Sharifian M, Jahromi AH, Shaabani S, et al. Effect of zinc supplementation on triglyceride, cholesterol, LDL, and HDL levels in zinc-deficient hemodialysis patients. Ren Fail. 2009;31(9):798–801.CrossRef
23.
go back to reference Seet RCS, Lee C-YJ, Lim ECH, Quek AML, Huang H, Huang SH, et al. Oral zinc supplementation does not improve oxidative stress or vascular function in patients with type 2 diabetes with normal zinc levels. Atherosclerosis. 2011;219(1):231–9.CrossRef Seet RCS, Lee C-YJ, Lim ECH, Quek AML, Huang H, Huang SH, et al. Oral zinc supplementation does not improve oxidative stress or vascular function in patients with type 2 diabetes with normal zinc levels. Atherosclerosis. 2011;219(1):231–9.CrossRef
24.
go back to reference Freeman SR, Williams HC, Dellavalle RP. The increasing importance of systematic reviews in clinical dermatology research and publication. J Invest Dermatol. 2006;126(11):2357–60.CrossRef Freeman SR, Williams HC, Dellavalle RP. The increasing importance of systematic reviews in clinical dermatology research and publication. J Invest Dermatol. 2006;126(11):2357–60.CrossRef
25.
go back to reference Foster M, Petocz P, Samman S. Effects of zinc on plasma lipoprotein cholesterol concentrations in humans: A meta-analysis of randomised controlled trials. Atherosclerosis. 2010;210(2):344–52.CrossRef Foster M, Petocz P, Samman S. Effects of zinc on plasma lipoprotein cholesterol concentrations in humans: A meta-analysis of randomised controlled trials. Atherosclerosis. 2010;210(2):344–52.CrossRef
26.
go back to reference Payahoo L, Ostadrahimi A, Mobasseri M, Bishak YK, Farrin N, Jafarabadi MA, et al. Effects of zinc supplementation on the anthropometric measurements, lipid profiles and fasting blood glucose in the healthy obese adults. Advanced Pharmaceutical Bulletin. 2013;3(1):161–5. Payahoo L, Ostadrahimi A, Mobasseri M, Bishak YK, Farrin N, Jafarabadi MA, et al. Effects of zinc supplementation on the anthropometric measurements, lipid profiles and fasting blood glucose in the healthy obese adults. Advanced Pharmaceutical Bulletin. 2013;3(1):161–5.
27.
go back to reference Rahimi-Ardabili B, Argani H, Ghorbanihaghjo A, Rashtchizadeh N, Naghavi-Behzad M, Ghorashi S, et al. Paraoxonase enzyme activity is enhanced by zinc supplementation in hemodialysis patients. Ren Fail. 2012;34(9):1123–8.CrossRef Rahimi-Ardabili B, Argani H, Ghorbanihaghjo A, Rashtchizadeh N, Naghavi-Behzad M, Ghorashi S, et al. Paraoxonase enzyme activity is enhanced by zinc supplementation in hemodialysis patients. Ren Fail. 2012;34(9):1123–8.CrossRef
28.
go back to reference Li Y, Wang C, Zhu K, Feng RN, Sun CH. Effects of multivitamin and mineral supplementation on adiposity, energy expenditure and lipid profiles in obese Chinese women. Int J Obes. 2010;34(6):1070–7.CrossRef Li Y, Wang C, Zhu K, Feng RN, Sun CH. Effects of multivitamin and mineral supplementation on adiposity, energy expenditure and lipid profiles in obese Chinese women. Int J Obes. 2010;34(6):1070–7.CrossRef
29.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRef
30.
go back to reference Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef
31.
go back to reference Higgins IP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRef Higgins IP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRef
32.
go back to reference Rugge B, Balshem H, Sehgal R, Relevo R, Gorman P, Helfand M: Screening and treatment of subclinical hypothyroidism or hyperthyroidism. 2011 Rugge B, Balshem H, Sehgal R, Relevo R, Gorman P, Helfand M: Screening and treatment of subclinical hypothyroidism or hyperthyroidism. 2011
33.
go back to reference Foster M, Petocz P, Caterson ID, Samman S: Effects of zinc and α-linolenic acid supplementation on glycemia and lipidemia in women with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Journal of Diabetes Research and Clinical Metabolism. 2013;2(1):3. Foster M, Petocz P, Caterson ID, Samman S: Effects of zinc and α-linolenic acid supplementation on glycemia and lipidemia in women with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Journal of Diabetes Research and Clinical Metabolism. 2013;2(1):3.
34.
go back to reference Farvid MS, Siassi F, Jalali M, Hosseini M, Saadat N. The impact of vitamin and/or mineral supplementation on lipid profiles in type 2 diabetes. Diabetes Res Clin Pract. 2004;65(1):21–8.CrossRef Farvid MS, Siassi F, Jalali M, Hosseini M, Saadat N. The impact of vitamin and/or mineral supplementation on lipid profiles in type 2 diabetes. Diabetes Res Clin Pract. 2004;65(1):21–8.CrossRef
35.
go back to reference Boukaïba N, Flament C, Acher S, Chappuis P, Piau A, Fusselier M, et al. A physiological amount of zinc supplementation: effects on nutritional, lipid, and thymic status in an elderly population. Am J Clin Nutr. 1993;57(4):566–72. Boukaïba N, Flament C, Acher S, Chappuis P, Piau A, Fusselier M, et al. A physiological amount of zinc supplementation: effects on nutritional, lipid, and thymic status in an elderly population. Am J Clin Nutr. 1993;57(4):566–72.
36.
go back to reference Black MR, Medeiros DM, Brunett E, Welke R. Zinc supplements and serum lipids in young adult white males. Am J Clin Nutr. 1988;47(6):970–5. Black MR, Medeiros DM, Brunett E, Welke R. Zinc supplements and serum lipids in young adult white males. Am J Clin Nutr. 1988;47(6):970–5.
37.
go back to reference Bogden JD, Oleske JM, Lavenhar MA, Munves EM, Kemp FW, Bruening KS, et al. Zinc and immunocompetence in elderly people: effects of zinc supplementation for 3 months. Am J Clin Nutr. 1988;48(3):655–63. Bogden JD, Oleske JM, Lavenhar MA, Munves EM, Kemp FW, Bruening KS, et al. Zinc and immunocompetence in elderly people: effects of zinc supplementation for 3 months. Am J Clin Nutr. 1988;48(3):655–63.
38.
go back to reference Chevalier CA, Murphy MD, Suneson J, Vanbeber AD, Gorman MA, Cochran C. The effects of zinc supplementation on serum zinc and cholesterol concentrations in hemodialysis patients. J Ren Nutr. 2002;12(3):183–9.CrossRef Chevalier CA, Murphy MD, Suneson J, Vanbeber AD, Gorman MA, Cochran C. The effects of zinc supplementation on serum zinc and cholesterol concentrations in hemodialysis patients. J Ren Nutr. 2002;12(3):183–9.CrossRef
39.
go back to reference Crouse SF, Hooper PL, Atterbom HA, Papenfuss RL. Zinc ingestion and lipoprotein values in sedentary and endurance-trained men. J Am Med Assoc. 1984;252(6):785–7.CrossRef Crouse SF, Hooper PL, Atterbom HA, Papenfuss RL. Zinc ingestion and lipoprotein values in sedentary and endurance-trained men. J Am Med Assoc. 1984;252(6):785–7.CrossRef
40.
go back to reference Feillet-Coudray C, Meunier N, Bayle D, Brandolini-Bunlon M, Andriollo-Sanchez M, O’Connor JM, et al. Effect of zinc supplementation on in vitro copper-induced oxidation of low-density lipoproteins in healthy French subjects aged 55–70 years: the Zenith Study. The British Journal Of Nutrition. 2006;95(6):1134–42.CrossRef Feillet-Coudray C, Meunier N, Bayle D, Brandolini-Bunlon M, Andriollo-Sanchez M, O’Connor JM, et al. Effect of zinc supplementation on in vitro copper-induced oxidation of low-density lipoproteins in healthy French subjects aged 55–70 years: the Zenith Study. The British Journal Of Nutrition. 2006;95(6):1134–42.CrossRef
41.
go back to reference Hininger-Favier I, Andriollo-Sanchez M, Arnaud J, Meunier N, Bord S, Graham C, et al. Age- and sex-dependent effects of long-term zinc supplementation on essential trace element status and lipid metabolism in European subjects: the Zenith Study. The British Journal Of Nutrition. 2007;97(3):569–78.CrossRef Hininger-Favier I, Andriollo-Sanchez M, Arnaud J, Meunier N, Bord S, Graham C, et al. Age- and sex-dependent effects of long-term zinc supplementation on essential trace element status and lipid metabolism in European subjects: the Zenith Study. The British Journal Of Nutrition. 2007;97(3):569–78.CrossRef
42.
go back to reference Khan MI, Siddique KU, Ashfaq F, Ali W, Reddy HD, Mishra A. Effect of high-dose zinc supplementation with oral hypoglycemic agents on glycemic control and inflammation in type-2 diabetic nephropathy patients. J Nat Sci Biol Med. 2013;4(2):336–40.CrossRef Khan MI, Siddique KU, Ashfaq F, Ali W, Reddy HD, Mishra A. Effect of high-dose zinc supplementation with oral hypoglycemic agents on glycemic control and inflammation in type-2 diabetic nephropathy patients. J Nat Sci Biol Med. 2013;4(2):336–40.CrossRef
43.
go back to reference Shah DR, Singh PP, Gupta RC, Bhandari TK. Effect of oral zinc sulphate on serum lipids and lipoproteins in human subjects. Indian J Physiol Pharmacol. 1988;32(1):47–50. Shah DR, Singh PP, Gupta RC, Bhandari TK. Effect of oral zinc sulphate on serum lipids and lipoproteins in human subjects. Indian J Physiol Pharmacol. 1988;32(1):47–50.
44.
go back to reference Hercberg S, Bertrais S, Czernichow S, Noisette N, Galan P, Jaouen A, et al. Alterations of the lipid profile after 7.5 years of low-dose antioxidant supplementation in the SU.VI.MAX study. Lipids. 2005;40(4):335–42.CrossRef Hercberg S, Bertrais S, Czernichow S, Noisette N, Galan P, Jaouen A, et al. Alterations of the lipid profile after 7.5 years of low-dose antioxidant supplementation in the SU.VI.MAX study. Lipids. 2005;40(4):335–42.CrossRef
45.
go back to reference Federico AIP, Federico P, Del Rio A, Mellone MC, Catalano G, Federico P. Effects of selenium and zinc supplementation on nutritional status in patients with cancer of digestive tract. Eur J Clin Nutr. 2001;55:293–7.CrossRef Federico AIP, Federico P, Del Rio A, Mellone MC, Catalano G, Federico P. Effects of selenium and zinc supplementation on nutritional status in patients with cancer of digestive tract. Eur J Clin Nutr. 2001;55:293–7.CrossRef
46.
go back to reference Gunasekara P, Hettiarachchi M, Liyanage C, Lekamwasam S. Effects of zinc and multimineral vitamin supplementation on glycemic and lipid control in adult diabetes. Diabetes, metabolic syndrome and obesity: targets and therapy. 2011;4:53–60. Gunasekara P, Hettiarachchi M, Liyanage C, Lekamwasam S. Effects of zinc and multimineral vitamin supplementation on glycemic and lipid control in adult diabetes. Diabetes, metabolic syndrome and obesity: targets and therapy. 2011;4:53–60.
47.
go back to reference Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.CrossRef Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.CrossRef
48.
go back to reference Age-Related Eye Disease Study Research Group. The effect of five-year zinc supplementation on serum zinc, serum cholesterol and hematocrit in persons randomly assigned to treatment group in the age-related eye disease study: AREDS Report No. 7. The Journal Of Nutrition 2002, 132(4):697–702. Age-Related Eye Disease Study Research Group. The effect of five-year zinc supplementation on serum zinc, serum cholesterol and hematocrit in persons randomly assigned to treatment group in the age-related eye disease study: AREDS Report No. 7. The Journal Of Nutrition 2002, 132(4):697–702.
49.
go back to reference Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V. Treatment of Wilson’s disease with zinc. IX: Response of serum lipids, vol. 118. UNITED STATES: Elsevier; 1991. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V. Treatment of Wilson’s disease with zinc. IX: Response of serum lipids, vol. 118. UNITED STATES: Elsevier; 1991.
50.
go back to reference Freeland-Graves JH, Friedman BJ, Han WH, Shorey RL, Young R. Effect of zinc supplementation on plasma high-density lipoprotein cholesterol and zinc. Am J Clin Nutr. 1982;35(5):988–92. Freeland-Graves JH, Friedman BJ, Han WH, Shorey RL, Young R. Effect of zinc supplementation on plasma high-density lipoprotein cholesterol and zinc. Am J Clin Nutr. 1982;35(5):988–92.
51.
go back to reference Gatto LM, Samman S. The effect of zinc supplementation on plasma lipids and low-density lipoprotein oxidation in males. Free Radic Biol Med. 1995;19(4):517–21.CrossRef Gatto LM, Samman S. The effect of zinc supplementation on plasma lipids and low-density lipoprotein oxidation in males. Free Radic Biol Med. 1995;19(4):517–21.CrossRef
52.
go back to reference Hooper PL, Visconti L, Garry PJ, Johnson GE. Zinc lowers high-density lipoprotein-cholesterol levels. JAMA. 1980;244(17):1960–1.CrossRef Hooper PL, Visconti L, Garry PJ, Johnson GE. Zinc lowers high-density lipoprotein-cholesterol levels. JAMA. 1980;244(17):1960–1.CrossRef
53.
go back to reference Ranga Rao KV, Seshiah V, Kumar TV. Effect of zinc sulfate therapy on control and lipids in type I diabetes. Journal of the Diabetic Association of India. 1990;30(2):38–40. Ranga Rao KV, Seshiah V, Kumar TV. Effect of zinc sulfate therapy on control and lipids in type I diabetes. Journal of the Diabetic Association of India. 1990;30(2):38–40.
54.
go back to reference Samman S, Roberts DC. The effect of zinc supplements on lipoproteins and copper status. Atherosclerosis. 1988;70(3):247–52.CrossRef Samman S, Roberts DC. The effect of zinc supplements on lipoproteins and copper status. Atherosclerosis. 1988;70(3):247–52.CrossRef
55.
go back to reference Thurnham DI, Munoz N, Lu JB, Wahrendorf J, Zheng SF, Hambidge KM, et al. Nutritional and haematological status of Chinese farmers: the influence of 13.5 months treatment with riboflavin, retinol and zinc. Eur J Clin Nutr. 1988;42(8):647–60. Thurnham DI, Munoz N, Lu JB, Wahrendorf J, Zheng SF, Hambidge KM, et al. Nutritional and haematological status of Chinese farmers: the influence of 13.5 months treatment with riboflavin, retinol and zinc. Eur J Clin Nutr. 1988;42(8):647–60.
56.
go back to reference Jayawardena R, Ranasinghe P, Galappatthy P, Malkanthi R, Constantine G, Katulanda P. Effects of zinc supplementation on diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2012;4(1):13.CrossRef Jayawardena R, Ranasinghe P, Galappatthy P, Malkanthi R, Constantine G, Katulanda P. Effects of zinc supplementation on diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2012;4(1):13.CrossRef
57.
go back to reference Russell JC, Proctor SD. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol. 2006;15(6):318–30.CrossRef Russell JC, Proctor SD. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol. 2006;15(6):318–30.CrossRef
58.
go back to reference Koba S, Hirano T. [Dyslipidemia and atherosclerosis]. Nihon Rinsho. 2011;69(1):138–43. Koba S, Hirano T. [Dyslipidemia and atherosclerosis]. Nihon Rinsho. 2011;69(1):138–43.
59.
go back to reference Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: A clinicobiochemical perspective. Angiology. 2007;58(5):513–22.CrossRef Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: A clinicobiochemical perspective. Angiology. 2007;58(5):513–22.CrossRef
60.
go back to reference Superko HR. Beyond LDL Cholesterol Reduction. Circulation. 1996;94(10):2351–4.CrossRef Superko HR. Beyond LDL Cholesterol Reduction. Circulation. 1996;94(10):2351–4.CrossRef
61.
go back to reference Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ. 2009;338. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ. 2009;338.
62.
go back to reference Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL Cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301–10.CrossRef Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL Cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301–10.CrossRef
63.
go back to reference Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):7404. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):7404.
64.
go back to reference Hokanson J, Austin M. Plasma triglyceride is a risk factor for cardiovascular disease independent of HDL cholesterol level; A Meta analysis of population based prospective studies. J Cardiovasc Risk. 1996;3(2):213–9.CrossRef Hokanson J, Austin M. Plasma triglyceride is a risk factor for cardiovascular disease independent of HDL cholesterol level; A Meta analysis of population based prospective studies. J Cardiovasc Risk. 1996;3(2):213–9.CrossRef
65.
go back to reference Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10 158 incident cases among 262 525 participants in 29 Western erospective studies. Circulation. 2007;115(4):450–8.CrossRef Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10 158 incident cases among 262 525 participants in 29 Western erospective studies. Circulation. 2007;115(4):450–8.CrossRef
66.
go back to reference Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker P. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298(3):309–16.CrossRef Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker P. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298(3):309–16.CrossRef
67.
go back to reference Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A. NOnfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299–308.CrossRef Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A. NOnfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299–308.CrossRef
68.
go back to reference Freiberg JJ, Tybjærg-Hansen A, Jensen J, Nordestgaard BG. NOnfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008;300(18):2142–52.CrossRef Freiberg JJ, Tybjærg-Hansen A, Jensen J, Nordestgaard BG. NOnfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008;300(18):2142–52.CrossRef
69.
go back to reference Shaikh M, Wootton R, Nordestgaard BG, Baskerville P, Lumley JS, La Ville AE, et al. Quantitative studies of transfer in vivo of low density, Sf 12–60, and Sf 60–400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb Vasc Biol. 1991;11(3):569–77.CrossRef Shaikh M, Wootton R, Nordestgaard BG, Baskerville P, Lumley JS, La Ville AE, et al. Quantitative studies of transfer in vivo of low density, Sf 12–60, and Sf 60–400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb Vasc Biol. 1991;11(3):569–77.CrossRef
70.
go back to reference Nordestgaard BG, Tybjaerg-Hansen A, Lewis B. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. Arterioscler Thromb Vasc Biol. 1992;12(1):6–18.CrossRef Nordestgaard BG, Tybjaerg-Hansen A, Lewis B. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. Arterioscler Thromb Vasc Biol. 1992;12(1):6–18.CrossRef
71.
go back to reference Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626–35.CrossRef Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626–35.CrossRef
72.
go back to reference Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract End Met. 2009;5(3):150–9.CrossRef Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract End Met. 2009;5(3):150–9.CrossRef
73.
go back to reference Franssen R, Monajemi H, Stroes ESG, Kastelein JJP. Obesity and Dyslipidemia. Med Clin North Am. 2011;95(5):893–902.CrossRef Franssen R, Monajemi H, Stroes ESG, Kastelein JJP. Obesity and Dyslipidemia. Med Clin North Am. 2011;95(5):893–902.CrossRef
74.
go back to reference Wanner C, Zimmermann J, Quaschning T, Galle J. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int Suppl. 1997;62:S53–55. Wanner C, Zimmermann J, Quaschning T, Galle J. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int Suppl. 1997;62:S53–55.
75.
go back to reference Assmann G, Gotto AM. HDL Cholesterol and protective factors in atherosclerosis. Circulation. 2004;109(23 suppl 1)):III-8–III-14. Assmann G, Gotto AM. HDL Cholesterol and protective factors in atherosclerosis. Circulation. 2004;109(23 suppl 1)):III-8–III-14.
76.
go back to reference Khoja SM, Marzouki ZM, Ashry KM, Hamdi SA. Effect of dietary zinc deficiency on rat lipid concentrations. Saudi Med J. 2002;23(1):82–6. Khoja SM, Marzouki ZM, Ashry KM, Hamdi SA. Effect of dietary zinc deficiency on rat lipid concentrations. Saudi Med J. 2002;23(1):82–6.
77.
go back to reference Koo SI, Lee CC. Cholesterol and apolipoprotein distribution in plasma high-density-lipoprotein subclasses from zinc-deficient rats. Am J Clin Nutr. 1989;50(1):73–9. Koo SI, Lee CC. Cholesterol and apolipoprotein distribution in plasma high-density-lipoprotein subclasses from zinc-deficient rats. Am J Clin Nutr. 1989;50(1):73–9.
78.
go back to reference Jenner A, Ren M, Rajendran R, Ning P, Huat BT, Watt F, et al. Zinc supplementation inhibits lipid peroxidation and the development of atherosclerosis in rabbits fed a high cholesterol diet. Free Radic Biol Med. 2007;42(4):559–66.CrossRef Jenner A, Ren M, Rajendran R, Ning P, Huat BT, Watt F, et al. Zinc supplementation inhibits lipid peroxidation and the development of atherosclerosis in rabbits fed a high cholesterol diet. Free Radic Biol Med. 2007;42(4):559–66.CrossRef
79.
go back to reference Mocchegiani E, Giacconi R, Malavolta M. Zinc signalling and subcellular distribution: emerging targets in type 2 diabetes. Trends Mol Med. 2008;14(10):419–28.CrossRef Mocchegiani E, Giacconi R, Malavolta M. Zinc signalling and subcellular distribution: emerging targets in type 2 diabetes. Trends Mol Med. 2008;14(10):419–28.CrossRef
80.
go back to reference Lynch CJ, Patson BJ, Goodman SA, Trapolsi D, Kimball SR. Zinc stimulates the activity of the insulin- and nutrient-regulated protein kinase mTOR. Am J Physiol Endocrinol Metabvol. 2001;281(1):E25–34. Lynch CJ, Patson BJ, Goodman SA, Trapolsi D, Kimball SR. Zinc stimulates the activity of the insulin- and nutrient-regulated protein kinase mTOR. Am J Physiol Endocrinol Metabvol. 2001;281(1):E25–34.
81.
go back to reference X-h T, Shay NF. Zinc has an insulin-like effect on glucose transport mediated by phosphoinositol-3-kinase and akt in 3 t3-l1 fibroblasts and adipocytes. J Nutr. 2001;131(5):1414–20. X-h T, Shay NF. Zinc has an insulin-like effect on glucose transport mediated by phosphoinositol-3-kinase and akt in 3 t3-l1 fibroblasts and adipocytes. J Nutr. 2001;131(5):1414–20.
82.
go back to reference Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106(4):453–8.CrossRef Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106(4):453–8.CrossRef
83.
go back to reference Dieck H, Döring F, Fuchs D, Roth H-P, Daniel H. Transcriptome and proteome analysis identifies the pathways that increase hepatic lipid accumulation in Zinc-deficient rats. J Nutr. 2005;135(2):199–205. Dieck H, Döring F, Fuchs D, Roth H-P, Daniel H. Transcriptome and proteome analysis identifies the pathways that increase hepatic lipid accumulation in Zinc-deficient rats. J Nutr. 2005;135(2):199–205.
84.
go back to reference Saper RB, Rash R. Zinc: An essential micronutrient. Am Fam Physician. 2009;79(9):768. Saper RB, Rash R. Zinc: An essential micronutrient. Am Fam Physician. 2009;79(9):768.
Metadata
Title
Effects of Zinc supplementation on serum lipids: a systematic review and meta-analysis
Authors
Priyanga Ranasinghe
WS Wathurapatha
MH Ishara
R. Jayawardana
P. Galappatthy
P. Katulanda
GR Constantine
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Nutrition & Metabolism / Issue 1/2015
Electronic ISSN: 1743-7075
DOI
https://doi.org/10.1186/s12986-015-0023-4

Other articles of this Issue 1/2015

Nutrition & Metabolism 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine